Bristol-Meyers Squibb In Class Action Over $2B Fraud

Law360, New York (October 19, 2005, 12:00 AM EDT) -- Drug maker Bristol-Meyers Squibb misled investors in a multi-billion dollar scheme to exaggerate demand its most popular products, according to a complaint filed Wednesday in federal court.

The class action was filed in U.S. District Court for the Southern District of New York on behalf of investors in Bristol-Meyers Squibb’s securities between October 19, 1999 and March 10, 2003. The suit claims the securities fraud was known to chief executive officer Peter R. Dolan, among others.

“The defendants named in this action engaged in a fraudulent...
To view the full article, register now.